Petlife Pharmaceuticals, Inc.
Other OTCTotal Valuation
Petlife Pharmaceuticals, Inc. carries a market capitalization of 39,350.00, placing it among publicly traded companies globally.
| Market Cap | 39,350.00 |
| Enterprise Value | N/A |
Share Statistics
Petlife Pharmaceuticals, Inc. currently has 80.26M shares outstanding.
| Shares Outstanding | 80.26M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 0.00 |
| P/TBV Ratio | -0.02 |
| P/FCF Ratio | -0.15 |
| P/OCF Ratio | -0.15 |
Financial Position
Petlife Pharmaceuticals, Inc. maintains a current ratio of 0.00, meaning it holds 0.0x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 0.00 |
| Quick Ratio | 0.00 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | -4.78 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -20,124.61 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Petlife Pharmaceuticals, Inc.'s stock has gained approximately 100.00001% over the past 52 weeks. The 50-day moving average sits at 0.00, while the 200-day moving average is 0.00.
| Beta (5Y) | N/A |
| 52-Week Price Change | 100.00001% |
| 50-Day Moving Average | 0.00 |
| 200-Day Moving Average | 0.00 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -2.39M, while operating income came in at -2.39M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -2.39M |
| Pretax Income | -3.71M |
| Net Income | -3.71M |
| EBITDA | -2.39M |
| EBIT | -2.39M |
| Earnings Per Share (EPS) | -0.05 |
Balance Sheet
Total book value stands at -31.20M, with working capital of -1.97M providing operational flexibility.
| Cash & Cash Equivalents | 7,856.00 |
| Total Debt | N/A |
| Net Debt | 793,798.00 |
| Equity (Book Value) | -31.20M |
| Book Value Per Share | -0.44 |
| Working Capital | -1.97M |
Cash Flow
Petlife Pharmaceuticals, Inc. produced -261,905.00 in operating cash flow over the past twelve months.
| Operating Cash Flow | -261,905.00 |
| Capital Expenditures | N/A |
| Free Cash Flow | -261,905.00 |
| FCF Per Share | 0.00 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -696.66 |
| FCF Yield | -677.48 |
Stock Splits
Petlife Pharmaceuticals, Inc.'s most recent stock split took place on September 12, 2016 with a 5:1 split ratio.
| Last Split Date | 9/12/2016 |
| Split Ratio | 5:1 |
Scores
Petlife Pharmaceuticals, Inc. posts an Altman Z-Score of -6,881.24, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -6,881.24 |